Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on endovascular robotics through its LIBERTY Endovascular Robotic System. The news around MBOT centers on the commercialization of this FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and the company’s progress in bringing it into routine clinical use.
Investors and clinicians following Microbot Medical can find updates on key commercial milestones, such as the limited market release of LIBERTY in selected high procedure volume regions in the U.S. and the company’s plans for a broader market release aligned with major medical conferences. News items also cover the first hospital adoption of LIBERTY for patient care at Emory University Hospital and the collaboration to build an Endovascular Robotics Program in interventional radiology.
Coverage of MBOT includes regulatory and clinical developments, including FDA 510(k) clearance for LIBERTY and reported data from the ACCESS PVI pivotal trial, where the company cites 100% robotic navigation success, a 92% reduction in radiation exposure and no adverse device events. Additional articles highlight Microbot Medical’s presence at professional meetings, its partnerships with third-party manufacturers and logistics providers, and its work on teleintervention and autonomous robotics collaborations.
Financial and corporate news for Microbot Medical features capital-raising activities through exercises of preferred investment options, as well as updates on its intellectual property portfolio, such as new patents in jurisdictions including Japan. For readers tracking MBOT, this news feed offers a focused view of how the company is advancing the LIBERTY System, expanding its commercial infrastructure and executing on its endovascular robotics strategy over time.
Microbot Medical (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for a third patent related to its LIBERTY® Robotic System by the USPTO. In 2021, the company secured three U.S. patents, bringing its total to 47 patents issued or allowed worldwide, with an additional 26 pending applications. CEO Harel Gadot stated that this year has been crucial for the LIBERTY system, highlighting the ongoing progress in IP and R&D. The granted claims protect a compact robotic device for surgical tool manipulation, reinforcing the company’s confidence in achieving its clinical goals for 2022.
Microbot Medical (Nasdaq: MBOT) is advancing the LIBERTY® Robotic System toward commercialization. Following a recent design freeze, Dr. Eyal Morag visited the U.S. to set up clinical infrastructure for an upcoming human trial expected to begin in late 2022. Dr. Morag emphasized the importance of aligning interests for key milestones, including an FDA pre-submission and the clinical trial. This marks a pivotal moment in advancing LIBERTY’s development, which aims to enhance clinical outcomes through innovative micro-robotic technologies.
Microbot Medical Inc. (MBOT) has achieved a significant milestone by reaching the design freeze for its LIBERTY Robotic System, marking a step towards commercialization. This milestone is based on extensive feasibility studies and physician feedback. The next step involves filing a pre-submission with the FDA in Q1 2022. A live demonstration of the LIBERTY System is scheduled for January 10th, 2022, in San Francisco. The company expresses confidence in advancing towards commercialization and aims to secure clinical sites for regulatory compliance.
Microbot Medical Inc. (Nasdaq: MBOT) announced a Notice of Allowance for a second patent regarding its LIBERTY® Robotic System from the USPTO. This brings the company's total to 46 patents issued/allowed and 24 pending applications. CEO Harel Gadot highlighted that the U.S. market is critical for LIBERTY® and emphasized the importance of protecting their intellectual property for future commercialization and shareholder value. The patent covers a modular robotic system for manipulating flexible surgical tools, enhancing innovation in medical devices.
Microbot Medical Inc. (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for its LIBERTY® Robotic System by the USPTO, marking a significant milestone in its intellectual property portfolio, which now consists of 45 patents issued/allowed and 24 pending applications. CEO Harel Gadot emphasized this achievement as crucial for securing a competitive edge and advancing commercialization of their technology aimed at enhancing catheter-based procedures while minimizing risks for physicians. The patent covers a device designed to automate the manipulation of surgical tools within bodily lumens.
Microbot Medical (Nasdaq: MBOT) announced a Notice of Allowance (NOA) for its 'One & Done' guidewire technology in China, adding to previous approvals in the European Union, Japan, and Israel. With a total of 44 patents allowed or issued and 24 pending globally, the company aims to enhance patient outcomes and strengthen its competitive position. The double guidewire technology includes features for adjusting curvature and stiffness, indicating advancements in micro-robotic applications for healthcare.
Microbot Medical (NASDAQ: MBOT) has strengthened its Scientific Advisory Board with the addition of Dr. Giora Weisz, a renowned interventional cardiologist. Dr. Weisz's extensive experience in robotic-enhanced coronary interventions, particularly his role in the FDA-approved CorePath system, is expected to aid Microbot in advancing its LIBERTY Robotic System. CEO Harel Gadot emphasized the significance of Dr. Weisz's involvement in enhancing the system to address the growing cardiac market. Microbot specializes in micro-robotic technologies aimed at improving patient outcomes.
Microbot Medical Inc. (Nasdaq: MBOT) has received a Notice of Allowance from the Israel Intellectual Property Office for its innovative 'One & Done' guidewire technology. This patent joins previously granted approvals in Europe and Japan, enhancing Microbot's global patent portfolio to 42 issued/allowed patents and 23 pending applications. CEO Harel Gadot emphasized the importance of this technology for the company's future development and competitive edge in the micro-robotic medical field.
Microbot Medical Inc. (Nasdaq: MBOT) has been notified by the Japan Patent Office (JPO) that it intends to grant a patent for its innovative ‘One & Done’ guidewire technology aimed at endoluminal interventions. This marks Japan as the second jurisdiction to recognize this patent, enhancing the company’s intellectual property protection. CEO Harel Gadot highlighted the positive feedback from the medical community regarding their LIBERTY™ Robotic system and noted that the allowed claims cover a dual guidewire structure with adjustable states. Currently, Microbot holds 41 issued patents and has 22 pending applications.
Microbot Medical Inc. (Nasdaq: MBOT) announced successful discussions with the FDA regarding its Self-Cleaning Shunt (SCS). The FDA's feedback allows the company to apply for an Early Feasibility Study (EFS), paving the way for a First-in-Human (FIH) clinical trial projected for Q3 2022. CEO Harel Gadot highlighted this as a significant milestone, noting confidence in the strength of their pre-clinical data. This innovative device aims to prevent obstruction in cerebrospinal fluid catheters for patients with hydrocephalus.